SEQUEL PHARMACEUTICALS INC

Profile

Company Names

SEQUEL PHARMACEUTICALS INC

Addresses

12790 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA 92130

12750 HIGH BLUFF DRIVE, SUITE 300, SAN DIEGO, CA 92130

Phone Numbers

(858) 509-0455

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

2007

State Incorporated:

DELAWARE

Total Amount Raised:

$5,373,034.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2010-12-21 
$1,000,000.00 
$9,000,000.00 
$8,000,000.00 
Debt 
2
2010-08-30 
$1,367,579.00 
$1,963,532.00 
$595,953.00 
Debt 
1
2009-08-03 
$3,005,455.00 
$8,412,727.00 
$5,407,272.00 
Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
PAUL 
 
CHAMBERLAIN 
EXECUTIVE OFFICER
SEQUEL PHARMACEUTICALS INC
STUART 
J.M. 
COLLINSON 
DIRECTOR
VERTEX PHARMACEUTICALS INC / MA   |  TIOGA PHARMACEUTICALS INC   |  SEQUEL PHARMACEUTICALS INC   |  AFFINIUM PHARMACEUTICALS LTD
HOWARD 
C. 
DITTRICH 
EXECUTIVE OFFICER
SEQUEL PHARMACEUTICALS INC   |  SORBENT THERAPEUTICS INC
BRIAN 
K. 
FARMER 
EXECUTIVE OFFICER
SEQUEL PHARMACEUTICALS INC
NINA 
 
KJELLSON 
DIRECTOR
LYCERA CORP   |  PRIMERA BIOSYSTEMS INC   |  PRIMERADX, INC.   |  ALVINE PHARMACEUTICALS INC   |  SEQUEL PHARMACEUTICALS INC   |  CNS THERAPEUTICS INC   |  TRIUS THERAPEUTICS INC   |  CEBIX INCOPRATED   |  CEBIX INC   |  EIGER BIOPHARMACEUTICALS INC   |  OCERA THERAPEUTICS INC   |  WELLTOK, INC.   |  OCERA THERAPEUTICS, INC.   |  K2 THERAPEUTICS, INC.   |  CIDARA THERAPEUTICS, INC.   |  EIGER BIOPHARMACEUTICALS, INC.   |  ANNUM HEALTH, INC.   |  VINETI, INC.   |  TYRA BIOSCIENCES, INC.
DAVID 
 
LOWE 
DIRECTOR
SEQUEL PHARMACEUTICALS INC   |  CHARITY PARTNERS INC.   |  AEGLEA BIOTHERAPEUTICS HOLDINGS, LLC   |  AMARANTUS BIOSCIENCE HOLDINGS, INC.   |  DELOS PHARMACEUTICALS, INC.   |  INSIGNIA CAPITAL PARTNERS II, L.P.   |  INSIGNIA CAPITAL PARTNERS II-A, L.P.
MARK 
 
MURGERDITCHIAN 
EXECUTIVE OFFICER
SEQUEL PHARMACEUTICALS INC
JOSEPH 
 
TURNER 
DIRECTOR
SEQUEL PHARMACEUTICALS INC   |  KYTHERA BIOPHARMACEUTICALS INC   |  TASKEASY, INC.   |  2014 ENCORE KENTUCKY 10-WELL   |  2014-B ENCORE KENTUCKY 10-WELL   |  ENCORE SOUTHERN KENTUCKY 10-WELL   |  ABALONE BIO A SERIES OF SHARDING HOLDINGS MANAGEMENT LLC   |  WEATHERWAX SPV A SERIES OF SHARDING HOLDINGS MANAGEMENT LLC   |  EPIBONE SPV - SHARDING HOLDINGS MANAGEMENT LLC   |  ATOMIC INDUSTRIES SPV - SHARDING HOLDINGS MANAGEMENT LLC   |  ADDITIVE SPACE SPV - SHARDING HOLDINGS MANAGEMENT LLC   |  SPARK NEURO SPV - ALLOCATIONS FUNDS LLC   |  BLACKROCK NEUROTECH SPV - ALLOCATIONS FUNDS LLC   |  HAVOCAI INC.
DANIEL 
K. 
TURNER, III 
DIRECTOR
SEQUEL PHARMACEUTICALS INC
ECKARD 
 
WEBER 
DIRECTOR
SEQUEL PHARMACEUTICALS INC   |  TOBIRA THERAPEUTICS, INC.   |  ASCENTA THERAPEUTICS, INC.   |  ADYNXX INC   |  TRAGARA PHARMACEUTICALS, INC.   |  OCERA THERAPEUTICS, INC.   |  SANTA MARIA BIOTHERAPEUTICS, INC.   |  PINTA BIOTHERAPEUTICS, INC.   |  NINA BIOTHERAPEUTICS, INC.   |  OREXIGEN THERAPEUTICS, INC.   |  ADYNXX, INC.   |  ADASTRA PHARMACEUTICALS, INC.
RANDALL 
 
WOODS 
EXECUTIVE OFFICER, DIRECTOR
SEQUEL PHARMACEUTICALS INC   |  SELEXAGEN THERAPEUTICS, INC.   |  SORBENT THERAPEUTICS INC
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2010-12-23
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Debt 
2010-12-21 
2010-09-07
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Debt 
2010-08-30 
2009-08-11
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Debt 
2009-08-03 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#